Litcius/Paper detail

Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling

Xun Sun, Kexin Li, Misato Hase, Rongrong Zha, Feng Yan, Bai‐Yan Li, Hiroki Yokota

2021Theranostics69 citationsDOIOpen Access PDF

Abstract

: In contrast to inducing tumor-enhancing secretomes and chemoresistance in general by inhibiting varying oncogenic pathways in chemotherapy, this study presented the unexpected outcome of generation tumor-suppressive secretomes by activating the pro-tumorigenic Wnt pathway. The results shed light on the contrasting role of oncogenic signaling in tumor cells and osteoblast-derived secretomes, suggesting a counterintuitive option for the treatment of breast cancer-associated bone metastasis.

Topics & Concepts

Cancer researchWnt signaling pathwayLRP5MoesinCancerBreast cancerOsteoblastBone metastasisBiologySignal transductionMedicineCell biologyCellInternal medicineIn vitroCytoskeletonGeneticsBiochemistryEzrinBone health and treatmentsBone Metabolism and DiseasesWnt/β-catenin signaling in development and cancer
Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling | Litcius